From M r W G Everet t Addenbrooke's Hospital, Cambridge Dear Sir, I was interested in the report by Eke & Warrington <September Journal, p 653) of three cases of heterotopic ossification occurring in abdominal scars. It is a condition whose aetiology is ill-understood and which requires greater recognition.
As the number of reports in the literature is small, perhaps I may be allowed to mention three cases that I have seen in the last six years. Two presented with a swelling in the abdominal wound, one and two years respectively, after colectomy for cancer, and this was thought to be due to local recurrence. One patient developed pain and tenderness of the wound one month after surgery; eventually a lump appeared leading to exploration and removal of heterotopic bone.
The theory of implantation of periosteum or perichondrium (Nilsson & Simonsson 1977) is an attractive one and could explain the fact that almost all reported cases of ossification have been in longitudinal abdominal incisions. One can well understand that damage to the xiphoid or costal cartilage may occur in upper midline or paramedian incisions. One of my cases had a transverse upper abdominal muscle cutting incision, but this was extended laterally to the costal margin and the costal cartilage could have been damaged. In another case heterotopic ossification occurred in a lower paramedian incision which was carried right down to the pubic symphysis. It would be interesting to know if this condition has ever been encountered with an incision which has not reached the upper or lower extremities of the abdomen. I doubt if the type of suture material used is important. Continuous monofilament nylon was used in my three cases. I would question whether prophylactic radiotherapy is necessary following heterotopic bone excision. Two of my patients, in whom the scar was simply excised, have been followed up for one and six years respectively without further trouble. Yours sincerely WGEVERETT 28 September 1981 Reference NilssonF & Slmonsson N (1977) Acta Chirurgica Scandinavica 143,435-437 Naloxone inanorexia nervosa
From Professor Ivor H Mills Department ofMedicine Addenbrooke's Hospital, Cambridge
Dear Sir, I was interested in the comments of Drs Gillman and Lichtigfeld (August Journal, p 631). I should assure these doctors and your readers that the patients with anorexia nervosa who were treated with naloxone (February, p 129) were all in wards with nurses specially trained in dealing with this condition. I think we can be sure from their expert observations and assessments of urinary pH, urinary ketones, etc., that these patients were not vomiting during their control periods and that naloxone could, therefore, not have operated through a mechanism decreasing vomiting. Yours faithfully IVORHMILLS 10Septem ber 1981
High levels ofcreatine phosphokinase in untreated myxoedema
From Dr H A I-Hillawi, Dr N T Cooke and Dr T R Price Middlesex Hospital, London WIN 8AA
Dear Sir, We have recently seen a 40-year-old Caucasian man with untreated myxoedema. The following table shows his initial serum thyroxine (ST) and thyroxine stimulating hormone (TSH) levels and the response to treatment. The creatine phosphokinase (CP) level on presentation was 43 times the upper limit of normal and fell within normal limits within five weeks of treatment. There was no evidence of muscle weakness at presentation.
CP
ST TSH (iu/I) ( Raised serum enzymes are recognized in untreated myxoedema (Doran 1978), but we are unaware of such elevated levels of creatine phosphokinase occurring in this situation. The cause of serum enzyme elevation in myxoedema remains unknown, but it is thought to be due to increased rates of leakage of enzymes from cells, coupled with a decreased rate of enzyme clearance from the circulation (Doran 1978 
